Mobile

A Phase 3, randomized, open label, comparator-controlled, parallel-group, multicentre study to compare the effects of exenatide and insulin glargine on beta cell function and cardiovascular risk marke...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000577-65

A Phase 3, randomized, open label, comparator-controlled, parallel-group, multicentre study to compare the effects of exenatide and insulin glargine on beta cell function and cardiovascular risk markers in subjects with Type 2 diabetes treated with metformin who have not achieved target HbA1c

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare beta function (as measured by arginine stimulated insulin secretion during a hyperglycemic clamp) after 52 weeks of intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin. Open ended extension to compare the beta cell function after longer term therapy with exenatide or glargine in subjects with type 2 diabetes.

Critère d'inclusion

  • Type 2 diabetes mellitus

Liens